GEROPHARM Group of Companies signed a license agreement with Dong-A
ST for exclusive development and promotion of a new drug for type II
Under the signed agreement, GEROPHARM is gaining the right to sell DA-1229, a drug developed by Korean company Dong-A ST, in Russia, Ukraine and Kazakhstan.
DA-1229 is a drug of the class of dipeptidyl peptidase (DPP-4) inhibitors (gliptins) which are used for lowering blood glucose levels for patients with type II diabetes.
The effect of this class of drugs is based on insulin secretion stimulation by substances which are produced in the body but rapidly inactivated by a special enzyme (DPP-4). Gliptins inhibit the effect of this enzyme which results in an increased production of insulin. The advantage of this class of drugs is in its great safety profile: treatment with these drugs does not cause such adverse events as hypoglycaemia and weight gain.
Nowadays DPP-4 inhibitors take more than half of worldwide oral
anti-diabetic drug market, at the same time, Russian DPP4 inhibitor
market volume is around 2.5 billion roubles. Currently there are
5 registered manufacturers of drugs of the DPP-4 inhibitor class in
“We are interested in the development of our drug portfolio for diabetes treatment as this is one of our development priorities,” says Petr Rodionov. “Currently we are developing long-acting and rapid-acting analogue insulins and looking into promising oral hypoglycemic compounds which can be seamlessly added to our portfolio and will allow us to gain leading positions in the segment of anti-diabetic drugs. Under the agreement with our South Korean partner, we will be develop a finished dosage form of the new drug and register it in Russia, Kazakhstan and Ukraine. According to our plans, this drug will enter the market in 2017”.